Dr. Russell Richardson, Ph.D.

Claim this profile
Studies Heart Failure
Studies Hypertension
1 reported clinical trial
15 drugs studied

Clinical Trials Russell Richardson, Ph.D. is currently running

Image of trial facility.

Vascular Function in Pulmonary Arterial Hypertension

for

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone. With advancing age and in many disease states, deleterious adaptations in the production and sensitivity of these vasodilator and vasoconstrictor substances may be observed, leading to a reduction in skeletal muscle blood flow and compromised perfusion to the muscle tissue. Adequate perfusion is particularly important during exercise to meet the increased metabolic demand of the exercising tissue, and thus any condition that reduces tissue perfusion may limit the capacity for physical activity. As it is now well established that regular physical activity is a key component in maintaining cardiovascular health with advancing age, there is a clear need for further studies in populations where vascular dysfunction is compromised, with the goal of identifying the mechanisms responsible for the dysfunction and exploring whether these maladaptations may be remediable. Thus, to better understand the etiology of these vascular adaptations in health and disease, the current proposal is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease. While there are clearly a host of vasoactive substances which collectively act to govern vasoconstriction both at rest and during exercise, four specific pathways that may be implicated have been identified in these populations: Angiotensin-II (ANG-II), Endothelin-1 (ET-1), Nitric Oxide (NO), and oxidative stress.

Recruiting

2 awards

Phase 1

7 criteria

More about Russell Richardson, Ph.D.

Clinical Trial Related

17 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial

Treatments Russell Richardson, Ph.D. has experience with

  • Acetylcholine
  • Angiotensin-II
  • BH4
  • BQ-123
  • Fexofenadine
  • L-NMMA

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Russell Richardson, Ph.D. specialize in?

Is Russell Richardson, Ph.D. currently recruiting for clinical trials?

Are there any treatments that Russell Richardson, Ph.D. has studied deeply?

What is the best way to schedule an appointment with Russell Richardson, Ph.D.?

Is there any support for travel costs?